Read Larry Connors' blog – Short Term Trading Strategies
Advanced Viral Research Corp. (OTCBB: ADVR | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions in the United States. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company develops its products focusing on the treatment of systemic symptoms, such as cachexia (body wasting), loss of appetite and lethargy experienced by patients with advanced malignant cancer, HIV-AIDS, cardiovascular disease, sepsis, viral infections, and other diseases, as well as to treat as an aid in wound healing. Its also develops its products for use as an anti-inflammatory in conditions, such as rheumatoid arthritis; and palliative agent to minimize certain toxicities associated with chemo or immunotherapies. The company was founded in 1984 and is based in Yonkers, New York. With 789.99 million shares outstanding and 185,600 shares declared short as of July 2008, there is a failure to deliver in shares of ADVR. According to quarterly data provided by the SEC, there were still 30,823 shares of ADVR that were failing-to-deliver as of September 28, 2007.
Green Globe International Inc. (OTCBB: GGLB | Quote | Chart | News | PowerRating) through its subsidiaries, engages in the travel, tourism, and related green businesses worldwide. The company offers Voyager Network travel distribution platform providing direct access to reservation systems of various travel suppliers, including airlines, cruise lines, hotels, car rental companies, and providers of other travel amenities worldwide. It searches for availability and price for the itinerary suggested by the buyer over various direct connected suppliers and global distribution systems; and presents the aggregated result in the format preferred by the buyer. The company, formerly known as GTREX Capital, Inc., was incorporated in 1999 and is based in Murrieta, California. With 88.7 million shares outstanding and 209,300 shares declared short as of July 2008, there is a failure to deliver in shares of GGLB.
Intellect Neurosciences Inc. (OTCBB: ILNS | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders of the central nervous system. The company's product pipeline includes small molecules, monoclonal antibodies, and vaccines that address unmet needs in Alzheimer's disease and other indications, including ataxia, Parkinson's disease, Huntington's disease, diabetes, stroke, myelodysplastic syndromes, motor neuron disease (ALS and Lou Gehrig's disease), and radiation injury. Its lead drug candidate, OXIGON, is a chemically synthesized form of a small, potent, dual mode of action, naturally occurring molecule with potential as a disease-modifying agent for Alzheimer's disease and other therapeutic indications. OXIGON has completed human Phase Ia clinical trials. Intellect Neurosciences also develops immunotherapies (monoclonal antibodies and vaccines) to prevent or arrest the progression of Alzheimer's disease, while avoiding the risk of adverse reactions. The company also has various proprietary immunotherapy platforms, such as ANTISENILIN, RECALL-VAX, and BETA-VAX with patented drug candidates for both passive and active immunization against Alzheimer's disease. ANTISENILIN is a passive monoclonal antibody platform, and RECALL-VAX and BETA-VAX are platform technologies for vaccination. The company was founded in 2005 and is headquartered in New York, New York. With 30.89 million shares outstanding and 103,900 shares declared short as of July 2008, there is a failure to deliver in shares of ILNS.
Mass Megawatts Wind Power Inc. (OTCBB: MMGW | Quote | Chart | News | PowerRating) a development stage company, engages in the production of wind turbines and sale of wind generated electricity in the United States. It develops prototype wind energy production equipment. Mass Megawatts Wind Power intends to build, patent, and operate wind energy generated power plants utilizing its licensed MultiAxis Turbine technology. The company was founded in 1997 under the name as Mass Megawatts, Inc. and changed its name to Mass Megawatts Power, Inc. in 2001. Further, it changed its name to Mass Megawatts Wind Power, Inc. in 2002. The company is based in Worcester, Massachusetts. With 4.75 million shares outstanding and 16,300 shares declared short as of July 2008, there is a failure to deliver in shares of MMGW.
Health Sciences Group Inc. (OTC: HESG | Quote | Chart | News | PowerRating) through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, an antioxidant derived from apple peels; and Edible Sponges, an open-cell hydrocolloid product. It sells its products primarily through mass market retailers, such as mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners, and other media. Health Sciences Group was founded in 1996 as Centurion Properties Development Corporation and changed its name to iGoHealthy.com in 2000. It changed its name to Health Sciences Group, Inc. in 2001. The company is based in Los Angeles, California. With 56.29 million shares outstanding and an undisclosed short position, there is a failure to deliver in shares of HESG. According to quarterly data provided by the SEC, there were still 30,182 shares of HESG that were failing-to-deliver as of August 17, 2007.
Exobox Technologies Corp. (OTC: EXBX | Quote | Chart | News | PowerRating) a development stage company, engages in the development of enterprise and home user endpoint and server security software products in the United States and internationally. Its technology is based on enforcing appropriate system and application behaviors by isolating and controlling real-time access to the file system, memory, network, and inter-process communication from unauthorized modifications. This technology provides endpoint computer and network security against various cyber threats, such as viruses, worms, trojans, host system compromises, spyware, and identity theft. Exobox's technology integrates into the operating system, which enables it to provide protection for the user's computer and network. The company was founded in 2002 and is headquartered in Houston, Texas. With 397.61 million shares outstanding and 9,500 shares declared short as of July 2008, there is a failure to deliver in shares of EXBX. According to quarterly data provided by the SEC, there were still 95,739 shares of EXBX that were failing-to-deliver as of September 28, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,050,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
